DFCI 11-237: A Feasibility trial of Everolimus (RAD001), an mTOR inhibitor, given in combination with multiagent re-induction chemotherapy in pediatric patients with relapsed acute lymphoblastic Leukemia (ALL)

  • Hijiya, Nobuko (PD/PI)

Project: Research project

Project Details

StatusFinished
Effective start/end date11/1/1310/31/18

Funding

  • Dana-Farber Cancer Institute
  • Novartis Pharmaceuticals Corporation